During its May 2017 meeting, EMA’s Committee for Medicinal Products for Human Use (CHMP) reviewed 12 recommendations for eligibility to PRIME: 5 were granted and 7 were denied. The EMA release on the meeting lists the individual product outcomes and provides a cumulative overview of recommendations on all PRIME eligibility requests submitted since the start of the program in April 2016. [For more on EMA’s PRIME program, see IPQ’s August/September and October/November 2016 Monthly Updates.]
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
